RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE
https://doi.org/10.21294/1814-4861-2019-18-4-13-20
Abstract
About the Authors
A. V. NovikRussian Federation
MD, PhD, Medical Oncologist,
68, Leningradskaya Street, 197758-St. Petersburg;
2A, Litovskaya Street, 194100-St. Petersburg
E. V. Yaremenko
Russian Federation
Student,
2A, Litovskaya Street, 194100-St. Petersburg
E. M. Anokhina
Russian Federation
MD, Postgraduate,
68, Leningradskaya Street, 197758-St. Petersburg
T. L. Nehaeva
Russian Federation
MD, PhD, Senior Scientist,
68, Leningradskaya Street, 197758-St. Petersburg
A. I. Semenova
Russian Federation
MD, PhD, Medical Oncologist,
68, Leningradskaya Street, 197758-St. Petersburg
D. Kh. Latipova
Russian Federation
MD, PhD, Medical Oncologist,
68, Leningradskaya Street, 197758-St. Petersburg
S. A. Protsenko
Russian Federation
MD, DSc, Medical Oncologist,
68, Leningradskaya Street, 197758-St. Petersburg
I. A. Baldueva
Russian Federation
MD, DSc, Associate Professor, Head of the Department of Oncoimmunology,
68, Leningradskaya Street, 197758-St. Petersburg;
41, Kirochnaya Street, 191015-St. Petersburg
References
1. Herzberg B., Fisher D.E. Metastatic melanoma and immunotherapy. Clin Immunol. 2016 Nov; 172: 105–110. doi: 10.1016/j. clim.2016.07.006.
2. Kim J.H. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. Oncotarget. 2016 Mar 22; 7(12): 13680–7. doi: 10.18632/oncotarget.7322.
3. Litiere S., Collette S., de Vries E.G., Seymour L., Bogaerts J. RECIST learning from the past to build the future. Nat Rev Clin Oncol. 2017 Mar; 14(3): 187–192. doi: 10.1038/nrclinonc.2016.195.
4. Fong L., Small E.J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008 Nov 10; 26(32): 5275–83. doi: 10.1200/JCO.2008.17.8954.
5. Wang Q., Gao J., Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018 May; 58: 125–135. doi: 10.1016/j.intimp.2018.03.018.
6. Wolchok J.D., Hoos A., O’Day S., Weber J.S., Hamid O., Lebbé C., Maio M., Binder M., Bohnsack O., Nichol G., Humphrey R., Hodi F.S. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1; 15(23): 7412–20. doi: 10.1158/1078-0432.CCR-09-1624
7. Hodi F.S., Hwu W.J., Kefford R., Weber J.S., Daud A., Hamid O., Patnaik A., Ribas A., Robert C., Gangadhar T.C., Joshua A.M., Hersey P., Dronca R., Joseph R., Hille D., Xue D., Li X.N., Kang S.P., Ebbinghaus S., Perrone A., Wolchok J.D. Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC). J Clin Oncol. 2016 May 1; 34(13): 1510–7. doi: 10.1200/JCO.2015.64.0391.
8. Di Giacomo A.M., Danielli R., Guidoboni M., Calabrò L., Carlucci D., Miracco C., Volterrani L., Mazzei M.A., Biagioli M., Altomonte M., Maio M. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009 Aug; 58(8): 1297–306. doi: 10.1007/ s00262-008-0642-y.
9. Novik A.V. Principles of modern immunotherapy. Farmateka. 2018; 7(360): 10–18. (in Russian). doi: 10.18565/pharmateca.2018.7.10-18.
10. Spiro J., Maintz D., Persigehl T. Response criteria for malignant melanoma: RECIST and irRC. Radiologe. 2015 Feb; 55(2): 127–35. doi: 10.1007/s00117-014-2763-y.
11. Novik A.V., Komarov Yu.I., Protsenko S.A., Semenova A.I., Baldueva I.A., Dubinina E.V., Pipia N.P., Akhaeva Z.Yu. Using if ipilimumab for teratmrnt patients with metastatic malignant melanoma of skin. Malignant tumors. 2014; 3: 60–3. (in Russian). doi: 10.18027/2224-5057-2014-3-60-63.
12. Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbé C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8): 711–23. doi: 10.1056/ NEJMoa1003466.
13. Nishino M., Giobbie-Hurder A., Gargano M., Suda M., Ramaiya N.H., Hodi F.S. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013 Jul 15; 19(14): 3936–43. doi: 10.1158/1078-0432.CCR-13-0895.
14. Ridolfi L., Petrini M., Fiammenghi L., Granato A.M., Ancarani V., Pancisi E., Brolli C., Selva M., Scarpi E., Valmorri L., Nicoletti S.V., Guidoboni M., Riccobon A., Ridolfi R. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res. 2011 Dec; 21(6): 524–9. doi: 10.1097/CMR.0b013e32834b58fa.
15. de Rosa F., Ridolfi L., Fiammenghi L., Petrini M., Granato A.M., Ancarani V., Pancisi E., Soldati V., Cassan S., Bulgarelli J., Framarini M., Tauceri F., Migliori G., Brolli C., Gentili G., Petracci E., Nanni O., Riccobon A., Ridolfi R., Guidoboni M. Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. Melanoma Res. 2017 Aug; 27(4): 351–357. doi: 10.1097/CMR.0000000000000356.
16. Lotem M., Merims S., Frank S., Hamburger T., Nissan A., Kadouri L., Cohen J., Straussman R., Eisenberg G., Frankenburg S., Carmon E., Alaiyan B., Shneibaum S., Ozge Ayyildiz Z., Isbilen M., Mert Senses K., Ron I., Steinberg H., Smith Y., Shiloni E., Gure A.O., Peretz T. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. J Immunol Res. 2016; 2016: 8121985. doi: 10.1155/2016/8121985.
17. Anokhina E.M., Novik A.V., Protsenko S.A., Baldueva I.A., Semiglazova T.Yu., Semenova A.I., Latipova D.Kh., Teletaeva G.M., Rubinchik V.N., Oganesyan A.P., Yaremenko E.V. Ipilimumab in patients with disseminated melanoma: the N.N. Petrov National Medical Research Center of Oncology Expanded Access Program experience. Problems of Oncology. 2018; 64: 388–92. (in Russian).
Review
For citations:
Novik A.V., Yaremenko E.V., Anokhina E.M., Nehaeva T.L., Semenova A.I., Latipova D.Kh., Protsenko S.A., Baldueva I.A. RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE. Siberian journal of oncology. 2019;18(4):13-20. (In Russ.) https://doi.org/10.21294/1814-4861-2019-18-4-13-20